Literature DB >> 10431609

Cell-based and animal models for hepatitis B and C viruses.

R F Schinazi1, E Ilan, P L Black, X Yao, S Dagan.   

Abstract

Reliable cell-based assays and animal models have been developed for evaluating agents against hepatitis B virus. Although much progress has been made, in vitro and in vivo assays for hepatitis C virus are still on the horizon. Advances towards establishing inexpensive and reliable experimental models have accelerated the development of therapeutic modalities for these life-threatening viral infections. The characterization of well-defined viral targets coupled with improved molecular diagnostic technologies have illuminated this field.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10431609     DOI: 10.1177/095632029901000301

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN: 0956-3202


  9 in total

1.  Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.

Authors:  Rachel Eren; Dorit Landstein; Dov Terkieltaub; Ofer Nussbaum; Arie Zauberman; Judith Ben-Porath; Judith Gopher; Rachel Buchnick; Riva Kovjazin; Ziva Rosenthal-Galili; Sigal Aviel; Ehud Ilan; Yariv Shoshany; Lewis Neville; Tal Waisman; Ofer Ben-Moshe; Alberto Kischitsky; Steven K H Foung; Zhen-Yong Keck; Orit Pappo; Ahmed Eid; Oded Jurim; Gidi Zamir; Eithan Galun; Shlomo Dagan
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

Review 2.  Hepatitis C virus experimental model systems and antiviral drug research.

Authors:  Susan L Uprichard
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

3.  Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.

Authors:  L Fu; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 4.  Hepatitis C virus infection--pathobiology and implications for new therapeutic options.

Authors:  Gary L Davis; Kris Krawczynski; Gyongyi Szabo
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

5.  Application of hepatitis B virus replication mouse model.

Authors:  Zhan Gao; Feng-Jun Liu; Li Liu; Tao-You Zhou; Jun Lei; Lu Xu; Cong Liu; Jie Dai; En-Qiang Chen; Hong Tang
Journal:  World J Gastroenterol       Date:  2010-04-28       Impact factor: 5.742

6.  Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.

Authors:  Raymond F Schinazi; Leda Bassit; Marcia M Clayton; Bill Sun; James J Kohler; Aleksandr Obikhod; Alla Arzumanyan; Mark A Feitelson
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

7.  A cellular model of inflammation for identifying TNF-alpha synthesis inhibitors.

Authors:  David Tweedie; Weiming Luo; Ryan G Short; Arnold Brossi; Harold W Holloway; Yazhou Li; Qian-sheng Yu; Nigel H Greig
Journal:  J Neurosci Methods       Date:  2009-07-05       Impact factor: 2.390

8.  Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication.

Authors:  Phuay-Yee Goh; Yee-Joo Tan; Siew Pheng Lim; Y H Tan; Seng Gee Lim; Frances Fuller-Pace; Wanjin Hong
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

9.  Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.

Authors:  Jie Dai; En-Qiang Chen; Lang Bai; Dao-Yin Gong; Qiao-Ling Zhou; Xing Cheng; Fei-Jun Huang; Hong Tang
Journal:  Virol J       Date:  2012-11-21       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.